CSF3R and myeloproliferative neoplasm, unclassifiable: For the differential diagnosis of CNL from all other neutrophilic leukemias (aCML, MDS/MPN-U, MPN-U, and ambiguous neutrophilic disorder), the CNL-5 risk model demonstrated a superior AUC (0.9071, p < 0.0001) compared to CSF3R mutation status (AUC = 0.7711, p = 0.0152) and peripheral neutrophil% (AUC = 0.